Overall incidence of prostate cancer decreased between 2003 and 2017.
Researchers tested a new decision support tool to optimize antibiotic prescribing for uncomplicated urinary tract infection.
A phase 3 randomized active-controlled trial will evaluate atezolizumab plus cabozantinib among patients with advanced RCC whose disease progressed with ICIs.
Patients who were Black, had higher incomes, or who had undergone surgery were less likely to receive palliative care.
A double-blind, placebo-controlled phase 3 trial is planned to evaluate cabozantinib plus nivolumab and ipilimumab as first-line treatment for advanced clear cell RCC..
A phase 3, randomized, active-controlled trial will evaluate the efficacy and safety of a HIF-2α inhibitor for the second-line treatment of clear cell RCC.
A modified dosing regimen of nivolumab-ipilimumab for patients with advanced RCC did not provide additional benefit compared with standard dosing.
A phase 2 trial has been initiated to evaluate a HIF-2α inhibitor for the treatment of advanced RCC after progression with another therapy.
A phase 3 randomized placebo-controlled trial is recruiting to evaluate nivolumab plus ipilimumab among patients with localized RCC at risk of relapse after nephrectomy.
Modified dosing of lenvatinib-everolimus did not improve tolerability and may have modestly decreased efficacy compared with standard dosing in advanced RCC.